title: FcγRIII in ITP: it ain't over 'til it's over.
abstract: In this issue of Blood, Yu et al describe a novel anti–Fcγ receptor III (FcγRIII)-albumin fusion protein that inhibits the development of thrombocytopenia in a murine model of immune thrombocytopenia (ITP).1 The unique aspect of this protein is that it blocks FcγRIII-mediated uptake of antibody-coated platelets without activating FcγRIII and the associated inflammatory response.
authors.affiliation: CLEVELAND CLINIC.
authors.forename: Keith R
authors.identifier: http://orcid.org/0000-0001-7340-475X
authors.initials: KR
authors.lastname: McCrae
mesh_terms: D000418:Albumins / Q000276:immunology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000276:immunology*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000628:therapy*; D017452:Receptors, IgG / Q000037:antagonists & inhibitors* / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology*
chemical_list: D000418:Albumins; D000911:Antibodies, Monoclonal; D007141:Immunoglobulin Fc Fragments; D017452:Receptors, IgG; D011993:Recombinant Fusion Proteins